Real-world data confirming the efficacy and safety of decitabine in acute myeloid leukaemia – results from a retrospective Belgian registry study

Stef Meersa Department Oncology, AZ Klina, Brasschaat, Belgium

Benjamin Baillyb Department Haematology, Groupe Jolimont, Haine Saint-Paul, Belgium

Isabelle Vande Broekc Department Oncology, AZ Nikolaas, Haematology, Sint Niklaas, Belgium

Bart Malfaitd Department Market Access, Janssen-Cilag NV, Beerse, Belgium

Sandra Van Hoorenbeeckd Department Market Access, Janssen-Cilag NV, Beerse, Belgium

Janice Geersd Department Market Access, Janssen-Cilag NV, Beerse, Belgium

Joost Braakmane Department Market Access, Janssen-Cilag BV, Breda, The Netherlands

Marieke Van Kouwenhovef Department Medical, Janssen-Cilag BV, Breda, The Netherlands

Margaret Doyleg Department Medical, Janssen Ireland, Dublin 24, Ireland

Joris Dielsh Department Statistics and Modelling, Janssen Pharmaceutica NV, Beerse, Belgium

Karin Caekelberghi Department Real-World Solutions, IQVIA, Zaventem, BelgiumCorrespondence[email protected]

Pierre Chevalieri Department Real-World Solutions, IQVIA, Zaventem, Belgium

Daan Dierickxj Department Haematology, UZ Leuven, Leuven, BelgiumDepartment Haematology

Your download is now in progress and you may close this window